主动脉瓣狭窄的终身管理:证据与共识专家综述
意大利心脏外科工作组对随机试验、荟萃分析及倾向匹配真实世界注册研究进行叙述性证据综述,从终身管理视角比较经股动脉TAVI与SAVR。证据提示TAVI早期非劣效性可能随随访延长而减弱,年轻低风险患者晚期死亡可能更高,再干预技术复杂度可能增加。
要点
- 2025 ESC/EACTS指南对≥70岁三叶瓣合适解剖患者经股TAVI给予I类推荐,年轻低风险仍推荐SAVR。
- TAVI早期非劣效性可能随随访延长而减弱,尤其预期寿命较长者。
- 经导管优先策略后再干预可能随时间增加技术复杂性和手术风险。
核心结论
- 经股TAVI常适用于预期寿命有限或明确高危且解剖可行的患者。
- 预期寿命较长者SAVR应保留为核心参考策略。
- 支持基于心脏团队个体化决策的务实框架应用现行指南。
研究设计与样本
- 意大利心脏外科工作组开展的叙述性、循证证据综述。
- 整合随机试验、基于试验的荟萃分析及倾向匹配真实世界注册研究。
- 主要聚焦低风险患者,仅在与终身管理、耐久性或再干预直接相关时纳入中低危证据。
主要发现
- 治疗效应呈时间依赖性:TAVI早期非劣效性可能随随访延长而减弱,尤其预期寿命较长者。
- 随机耐久性数据仍有限,倾向匹配真实世界注册提示年轻低风险人群TAVI后晚期死亡可能更高。
- 经导管优先策略后再干预可能随时间增加技术复杂性和手术风险。
关键数值与推荐
- 2025 ESC/EACTS指南对选定≥70岁三叶主动脉瓣狭窄且解剖合适的患者给予经股TAVI I类推荐。
- 年轻低风险患者仍推荐SAVR。
- 经股TAVI常适用于预期寿命有限或明确高危且解剖可行者。
- 预期寿命较长者SAVR应保留为核心参考策略。
临床怎么用
- 对预期寿命有限或明确高危且解剖可行者,经股TAVI常为合适选择。
- 对预期寿命较长者,SAVR应作为核心参考策略。
- 通过心脏团队个体化评估,整合耐久性、再干预风险和患者偏好进行终身管理决策。
局限性
- 随机耐久性数据仍有限。
- 证据整合以叙述性综述为主,非系统评价。
- 中低危证据仅在直接相关时纳入,覆盖有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The 2025 European Society of Cardiology/European Association for Cardio-Thoracic Surgery Guidelines introduced a Class I recommendation for transfemoral transcatheter aortic valve implantation (TAVI) in selected patients aged 70 years or older with tricuspid aortic stenosis and suitable anatomy, while surgical aortic valve replacement (SAVR) remains recommended in younger low-risk patients. In patients with long expected survival, this framework requires careful consideration of valve durability, future reintervention, and patient preferences. This expert review, developed by the Italian Cardiac Surgery Working Group, examines contemporary evidence and consensus recommendations from a lifetime-management perspective. METHODS: We performed a narrative, evidence-based synthesis of randomized trials, trial-based meta-analyses, and propensity-matched real-world registries comparing transfemoral TAVI and SAVR, with primary emphasis on low-risk patients. Lower-intermediate-risk evidence was included only when directly relevant to lifetime management, durability, or reintervention. RESULTS: Evidence suggests that treatment effects are time-dependent: early non-inferiority of TAVI may attenuate with longer follow-up, particularly in patients with substantial life expectancy. Randomized durability data remain limited, whereas propensity-matched real-world registries have suggested possible higher late mortality after TAVI in younger, lower-risk populations. Reintervention after a transcatheter-first strategy may be associated with increasing technical complexity and procedural risk over time. CONCLUSIONS: This review supports appropriate application of current guidelines through a pragmatic framework for individualized, Heart Team-based decision-making. Transfemoral TAVI is often appropriate in patients with limited life expectancy or recognized high surgical risk when anatomically feasible. In patients with long expected survival, SAVR should retain a central role as an important reference strategy.
引用
- Centofanti, Rinaldi, Di Eusanio, et al. Lifetime Management of Aortic Stenosis: Expert Review of Evidence and Consensus Guidelines. Ann Thorac Surg. 2026. PMID: 42933524. doi:10.1016/j.athoracsur.2026.09.062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。